Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Comparing Quality of Life (QOL) after adjuvant breast regional nodal radiotherapy (RNRT) within HYPORT Adjuvant trial (NCT03788213) Presented by SANJOY CHATTERJEE 🇮🇳 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Conventional vs Pelvic Ultra-Hypofractionated IMRT with HDR Brachytherapy in Prostate Cancer: Early Outcomes from PCS-XI Complete Cohort(NCT05820633) Presented by François Fabi 🇨🇦 #RadOnc ☢️ #ProstateCancer @estroradiotherapy.bsky.social

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Ten-year results of the IMPORT HIGH trial (ISRCTN47437448): Dose escalated simultaneous integrated boost radiotherapy in early breast cancer Presented by Charlotte Coles 🇬🇧 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Acute toxicity in PACE-NODES: A randomised trial of 5 fraction (f) prostate stereotactic body radiotherapy (SBRT) vs 5f prostate and pelvic nodal SBRT Presented by Angela Pathmanathan 🇬🇧 #RadOnc ☢️ #ProstateCancer @estroradiotherapy.bsky.social

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 DART: Darolutamide Added to Radiotherapy — A Randomised Phase II Trial of SBRT With or Without Darolutamide for Oligorecurrent Prostate Cancer Presenter Piet Ost 🇧🇪 #RadOnc @estroradiotherapy.bsky.social

Excited to see the HERMES trial results in print www.sciencedirect.com/science/arti... Small trial but toxicity of 2 fractions looks promising at 24/27 Gy, no GI tox of G2 or higher out to 12 weeks @momentumstudy.bsky.social @icr.ac.uk

What could be better than 5 days in Verona in October, learning about prostate cancer? Comprehensive multidisciplinary programme aimed at oncologists, urologists, radiologists and anyone else involved in treated prostate cancer. Spread the word!

Exciting data presented in ESTRO 2025 plenary: 5 fraction adjuvant breast RT (26 Gy) at least as good (and possibly better?) than 15 fractions @icr.ac.uk #ESTRO2025

Want to learn more about prostate radiotherapy contouring? Register for the ESTRO prostate contouring course- two evening sessions with me and @dannyvesprini.bsky.social More info here www.estro.org/Courses/2025...

Ever wondered if urethral dose explained the differential GU toxicity by platform in PACE-B? It appears not- credit to Dr Ragu Ratnakumaran @ijrobp.bsky.social eur01.safelinks.protection.outlook.com?url=https%3A...

ICYMI: *30* year outcomes from SPCG-4 dx.doi.org/10.1056/NEJM... RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm

First @bsky.app post! Happy to share our recently published review on screening guidelines for people at risk of prostate cancer in the Oct issue of the Canadian Urological Association Journal/CUAJ Led by #SunnybrookHSC genetic guru @justinlorentz.bsky.social cuaj.ca/index.php/jo...